Global
Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2018 (US$ Mn)
Prevalence of low sexual desire and
hypoactive sexual desire disorder in a nationally representative sample of US women.
Efficacy of flibanserin in women with
hypoactive sexual desire disorder: results from the BEGONIA trial.
[ClickPress, Fri Sep 11 2015] Global Markets Direct's, 'Female
Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2015', provides an overview of the Female
Hypoactive Sexual Desire Disorder's therapeutic pipeline.
-- The majority of a Food and Drug Administration advisory panel has supported the approval of flibanserin, an oral, centrally acting, nonhormonal drug taken once a day for
hypoactive sexual desire disorder in premenopausal women.
Male
hypoactive sexual desire disorder is defined as persistently or recurrently deficient (or absent) sexual/erotic thoughts or fantasies and desire for sexual activity [2,3] This may be the result of common medical conditions including substance-use disorders, social and interpersonal factors, or use of pharmacological agents.
Up to 20 percent of women may have this form of sexual dysfunction, called
hypoactive sexual desire disorder, for which there are no proven therapies, Dr.
A randomized, double-blind, placebo controlled study of the efficacy and safety of bupropion lot treating
hypoactive sexual desire disorder in ovulating women, BJU Int.
The diagnostic criteria for
Hypoactive Sexual Desire Disorder (HSDD) outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM; American Psychiatric Association, 2000) have generated a great deal of discussion and controversy (Basson et al., 2000; Brotto, 2010; Kaschak & Tiefer, 2002; Segraves, Balon, & Clayton, 2007).
Nonetheless, SSRIs are associated with a risk of clinically significant loss of sexual desire that may resemble moderate to severe
hypoactive sexual desire disorder. (17) Reduced mesolimbic dopaminergic activity as a result of inhibitory serotonergic midbrain raphe nuclei projections is 1 possible cause.
The FDA's Reproductive Health Drugs Advisory Committee voted 10-1 that the studies presented by Boehringer Ingelheim Pharmaceuticals did not provide enough evidence that flibanserin, a centrally acting drug, was an effective treatment for
hypoactive sexual desire disorder (HSDD), a persistent or recurrent deficiency or absence of desire for sexual activity.
Palatin Technologies (PTN) announced that the FDA has granted marketing approval of AMAG Pharmaceuticals' (AMAG) New Drug Application, or NDA, for Vyleesi, a melanocortin receptor agonist developed by Palatin indicated for the treatment of premenopausal women with acquired, generalized
hypoactive sexual desire disorder, or HSDD.
